M.Sc, Integrated M.Sc. in Botany, Biotechnology, Microbiology, Biochemistry, Bioinformatics, Life Sciences or B.Tech. in Computer Science from recognized University.
Work on research project entitled Engineering hybrid biological systems for self-sustainable treatment of persistent mobile chemicals in common effluent treatment plant wastewater funded by Gujarat State Biotechnology Mission, Govt. of Gujarat at Gujarat M.Sc Biotechnology, Microbiology, Biochemistry or relevant life science discipline with minimum of 55% marks. Biotechnology University.
Candidates having M.Sc. or an equivalent qualification in Life Sciences or related subjects Biotechnology, Biochemistry, Genetics, Microbiology, Bioinformatics with a minimum of 60% marks or an equivalent grade point relaxation will be as per Govt. guideline are eligible to apply.
Post-graduate degree in Basic Sciences or Professional Courses.
Candidates with 1-2 years of hands-on experience in mammalian cell culture, stem cell culture, molecular biology, RNA isolation/western blotting, FACS, microscopy imaging techniques are preferred. Those with experience in zebrafish and mouse model may also apply.
Lab Exposure, Analytical Method Validation. Review of Specification. Method of Analysis Protocol Handing of 00S and 00T. Investigation and Lab event. Review & Approval of QC Documents. Knowledge of Qualification and Validation related Activities. Audit Trail Review etc
Experience in pharmacovigilance, in clinical care, or in clinical or scientific research is an advantage but not a requirement. Demonstrated computer literacy, particularly in the use and management of relational databases.
Execute the Formulation Technology Transfer activities across all Cipla sites and CMO to standardize, strengthen and improve the technology transfer processes and systems in line with regulations
A new variant of human mpox has claimed the lives of approximately 5% of people with reported infections in the Democratic Republic of the Congo since 2023, many of them children. Since then, it has spread to several other countries. The World Health Organization declared the outbreak a Public Health Emergency of International Concern on August 14. In addition, a different but rarely fatal mpox variant was responsible for an outbreak that has spread to more than 100 countries since 2022.
RNA-based technology facilitates effective use for difficult-to-treat, large-gene diseases. Gene therapy can effectively treat various diseases, but for some debilitating conditions like muscular dystrophies there is a big problem: size. The genes that are dysfunctional in muscular dystrophies are often extremely large, and current delivery methods can’t courier such substantial genetic loads into the body.